Association between corneal temperature and mental status of treatment-resistant schizophrenia inpatients

References 

1. Bligh J. The central neurology of mammalian thermoregulation. Neuroscience. 1979;4:1213–1236
   • MEDLINE
   • CrossRef
2. Cape G. Neuroleptic malignant syndrome — a cautionary tale and a surprising outcome. British Journal of Psychiatry. 1994;164:120–122
3. Carlsson A, Lindquist M. Effect of chlorpromazine and haloperidol on formation of 3-methoxytyramine and norepinephrine in mouse brain. Acta Pharmacologica et Toxicologica. 1963;20:140
   • MEDLINE
   • CrossRef
4. Chong TWH, Castle DJ. Layer upon layer: thermoregulation in schizophrenia. Schizophrenia Research. 2004;69:149–157
   • Abstract
   • Full Text
   • Full-Text PDF (131 KB)
   • CrossRef
5. Clark WG. Changes in body temperature after administration of amino acids, peptides, dopamine, neuroleptics and related agents. Neuroscience and Biobehavioral Reviews. 1979;3:179–231
   • MEDLINE
   • CrossRef
6. Crandall CG, Vongpatanasin W, Victor RG. Mechanism of cocaine-induced hyperthermia in humans. Annals of Internal Medicine. 2002;136:785–791
7. Dilsaver SC. Effects of neuroleptics on body temperature. Journal of Clinical Psychiatry. 1988;49:78–79
8. Dixit S, Bushara K, Brooks B. Epidemic heat stroke in a midwest community: risk factors, neurological complications and sequelae. Wisconsin Medical Journal. 1997;96:39–41
   • MEDLINE
9. Heh C, Herrera J, Demet E, Potkin S, Costa J, Sramek J. Neuroleptic-induced hypothermia associated with amelioration of psychosis in schizophrenia. Neuropsychopharmacology. 1988;1:149–156
   • MEDLINE
   • CrossRef
10. Hermesh H, Shiloh R, Epstein Y, Manaim H, Weizman A, Munitz H. Heat intolerance in patients with chronic schizophrenia maintained with antipsychotic drugs. American Journal of Psychiatry. 2000;157:1327–1329
11. Kapur S, Remington G. Serotonin–dopamine interaction and its relevance to schizophrenia. American Journal of Psychiatry. 1996;153:466–476
12. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987;13:261–276
    • MEDLINE
13. Laborit H. Clinical hypothermia. In:  Lomax P,  Schonbaum E editor. Body Temperature Regulation; Drug Effects and Therapeutic Implications. New York: Dexter; 1979;p. 595–611
14. Lazarus A, Mann S, Caroff S. The Neuroleptic Malignant Syndrome and Related Conditions. Washington DC: American Psychiatric Press; 1989;
15. Levinson DF, Simpson GM. Neuroleptic-induced extrapyramidal symptoms with fever. Heterogeneity of the ‘neuroleptic malignant syndrome’. Archives of General Psychiatry. 1986;43:839–848
    • MEDLINE
16. Lindvall O, Bjorklund A, Skagerberg G. Dopamine-containing neurons in the spinal cord: anatomy and some functional aspects. Annals of Neurology. 1983;14:255–260
    • MEDLINE
    • CrossRef
17. Maeir U, Aigner J, Klein H. Hypothermia caused by neuroleptics. Two case reports and review of the literature. Nervenarzt. 1994;65:488–491
    • MEDLINE
18. Mapstone R. Determinants of corneal temperature. British Journal of Ophthalmology. 1968;52:729–741
19. Mosteller R. Simplified calculation of body surface area. New England Journal of Medicine. 1987;317:1098
20. Muller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. American Journal of Psychiatry. 2002;159:1029–1034
21. Overall J, Gorham D. The Brief Psychiatric Rating Scale. Psychological Reports. 1961;10:799–812
    • CrossRef
22. Rysa P, Sarvaranta J. Corneal temperature in man and rabbit. Acta Ophthalmologica. 1974;52:810–816
    • MEDLINE
23. Schwaninger M, Weisbrod M, Schwab S, Schroder M, Hacke W. Hypothermia induced by atypical neuroleptics. Clinical Neuropharmacology. 1998;21:344–346
    • MEDLINE
24. Shiloh R, Hermesh H, Weizer N, Dorfman_Etrog P, Weizman A, Munitz H. Acute antipsychotic drug administration lowers body temperature in drug-free male schizophrenic patients. European Neuropsychopharmacology. 2000;10:443–445
25. Shiloh R, Weizman A, Epstein Y, Rosenberg SL, Valevski A, Dorfman_Etrog P. Abnormal thermoregulation in drug-free male schizophrenia patients. European Neuropsychopharmacology. 2001;11:285–288
26. Shiloh R, Bodinger L, Katz N, Sigler M, Stryjer R, Hermesh H. Lower corneal temperature in neuroleptic-treated vs. drug-free schizophrenia patients. Neuropsychobiology. 2003;48:1–4
    • MEDLINE
    • CrossRef
27. Shiloh R, Portuguese S, Bodinger L, Katz N, Sigler M, Hermesh H. Increased corneal temperature in drug-free male schizophrenia patients. European Neuropsychopharmacology. 2003;13:49–52
28. Shiloh R, Munitz H, Portuguese S, Gross-Isseroff R, Sigler M, Bodinger L. Corneal temperature in schizophrenia patients. International Journal of Neuropsychopharmacology. 2005;8:537–547
29. Shiloh R, Munitz H, Stryjer R, Weizman A. A significant correlation between ward temperature and the severity of symptoms in schizophrenia inpatients — a longitudinal study. European Neuropsychopharmacology. 2007;17:478–482
30. Snyder SH. Biochemical factors in schizophrenia. Hospital Practice. 1977;12:133–140
    • MEDLINE
31. Snyder SH. Dopamine receptors, neuroleptics, and schizophrenia. American Journal of Psychiatry. 1981;138:460–464
32. Snyder SH. Neurotransmitters and CNS disease. Schizophrenia. Lancet. 1982;2:970–974
33. Snyder SH. Psychotogenic drugs as models for schizophrenia. Neuropsychopharmacology. 1988;1:197–199
    • MEDLINE
    • CrossRef